Navigation Links
Minnow Medical Bolsters Management Team

LAGUNA HILLS, Calif., Oct. 6 /PRNewswire/ -- Minnow Medical, Inc., a developer of a novel platform technology employing radiofrequency thermoplasty for the treatment of in-stent restenosis and other peripheral vascular conditions, announced today the appointment of two veteran medical device executives.

Prabodh Mathur has been named chief product development officer and Michael K. Handley has been named vice president of quality, clinical and regulatory affairs.

"Both Prabodh and Michael are experts in their respective fields and have the experience, drive and passion to assist Minnow in executing the remaining clinical, regulatory and product development activities necessary to gain clearance for the use of our ZCath™ System to treat occlusions in the leg arteries of patients with peripheral vascular disease," said Raymond W. Cohen, CEO of Minnow. "Minnow's technology has already been proven to be safe in human clinical studies in Europe. The goal of the new management team is to become one of the first companies to establish efficacy and gain U.S. Food and Drug Administration (FDA) clearance to treat patients who have already received stent implants in their peripheral leg arteries and are suffering from in-stent restenosis - a dangerous build-up of plaque inside the stents."  

About the Executives:Mathur is a seasoned technical executive with a proven track record of developing complex, innovative, Class III medical devices from concept, through design exploration, IP review, engineering, manufacturing transfer, regulatory clearance to market launch. Mathur held numerous engineering leadership positions, including chief technical officer, with publicly traded Cardiac Science over a 15-year period until 2009. Earlier, Mathur was, for nine years, vice president engineering of Medstone International, a manufacturer of transportable lithotripters.

Over the past years, Mathur has been involved in developing products including a catheter-based biopolymer delivery system, fully automatic public-access defibrillators, multi-parameter patient monitors, lithotripters, cryoablation delivery systems, therapeutic diode laser and fiber-optic delivery systems, and an industrial high-power carbon dioxide laser and robotic system.  Cumulative revenues from products designed under his leadership exceed $1 billion. Mathur holds a M.S. in Engineering from Missouri University of Science and Technology and a B.S. in Mechanical Engineering from Indian Institute of Technology in Kanpur, India.

Handley, who has more than a decade of quality, clinical and regulatory experience in the healthcare field, was until recently chief compliance officer, vice president of global regulatory affairs at publicly traded Spectranetics Corporation.  Handley joined Spectranetics in 2007 as manager of regulatory affairs and was promoted to director, global regulatory affairs and compliance and subsequently to chief compliance officer.

Prior to joining Spectranetics, Handley served as vice president, regulatory affairs for AccelaPure, a company providing pre-clinical and clinical services for biotechnology companies. Prior to that, Handley was senior principal at Pittiglio Rabin Todd & McGrath, a nationally-recognized management consulting firm for the biopharmaceutical and medical device industries. Handley holds a B.S. in Molecular Biology, Physiology, and minors in Chemistry and Neurobiology from Colorado State University and an M.B.A. from the Graziadio School of Business and Management at Pepperdine University.

About Minnow Medical, Inc. Minnow Medical, founded in 2003, is a privately-held, venture-backed development stage company developing novel radiofrequency thermoplasty technology directed toward patients with peripheral vascular disease. The Company is ISO 13485 Compliant and FDA registered.

Minnow's initial product, the ZCath System, combines a patented low-pressure percutaneous transluminal angioplasty balloon catheter combined with uniformed and controlled RF energy intended to safely reverse and prevent the progression of peripheral vascular disease by restoring blood flow, reducing plaque burden and reducing restenosis without vessel trauma. The product has advanced from pre-clinical to clinical stage testing and has achieved CE Mark for use in reducing plaque in peripheral leg arteries. The Company has also filed a 510(k) with the FDA seeking marketing clearance in the United States for the aforementioned clinical indication.

For more information on Minnow Medical, please visit the Company's website at or contact Matt Clawson at Allen & Caron Inc at 949-474-4300 or via email at matt@allencaron.comContact:

Matt ClawsonAllen & Caron

SOURCE Minnow Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Minnow Medical Names Raymond W. Cohen as Chief Executive Officer
2. CardioGenics Featured on Cover of Medical Device & Diagnostic Industry Magazine
3. Nonin Medical, Inc. Announces Capnography Division Name Change; Expands Swedish Manufacturing Facility to Become Full-Franchise European Sales, Distribution and Service Center
4. Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
5. Varian Medical Systems and IMRIS to Co-Develop Revolutionary New MR-Guided Radiation Therapy System
6. Detroit Medical Center Chooses CareTech Solutions Document Imaging System
7. Reprints Desk Survey Highlights Medical Marketers Key Challenges for Adopting and Using Clinical Reprints in Electronic Format
8. BridgePoint Medical®, Inc. Completes and Submits to FDA in the U.S. FAST-CTOs With the CrossBoss® and Stingray® CTO Recanalization System
9. RoundTable Healthcare Partners Portfolio Company, Argon Medical Devices, Inc., Acquires Critical Care and Extended Dwell Catheter Product Platforms From BD
10. PolyTouch Medical to Attend the American College of Surgeons 96th Annual Clinical Congress, Washington DC. (Booth #549)
11. American Medical Systems Strengthens Global Expansion With GreenLight HPS® Acquisitions in Australia
Post Your Comments:
(Date:11/24/2015)... YORK , Nov. 24, 2015 iRhythm Technologies, ... advancing cardiac care, today announced that it will participate in the ... Hotel in New York, NY . ... present on Tuesday December 1, 2015 at 8:50am ET. ... . --> . ...
(Date:11/24/2015)... 24, 2015 --> ... MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists ... grow at the fastest rates? This visiongain ... trends, opportunities and prospects there. ,  ,Our 199-page report ... lucrative areas in the industry and the future market ...
(Date:11/24/2015)... Inc., an industry leader in LCD screen protection and glare-elimination technology, is providing a vital solution ... patient monitoring or electronic documentation system. Photo - ... ... ... A study in 2013 by the National Institutes of ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five ... is critical that the first impression be positive and reflects business values. If a ... buy anything or want to return. They will also share their thoughts about a ...
(Date:11/24/2015)... PLAINSBORO, N.J. (PRWEB) , ... November 24, 2015 ... ... experts will gather to share their knowledge and experiences at a live taping ... during the Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at ...
(Date:11/24/2015)... ... 24, 2015 , ... Aided by seed funding from the Ron Foley Foundation, ... yield insights into how to detect and treat pancreatic cancer (PC). , WCHN ... non-coding RNA molecules (ncRNA), genetic material that is present in the blood of patients ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore ... TrustDale certification. The award recognizes good companies for excellence in service and a ... grout, and hard surface restoration company earned this recognition after a thorough review ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of patented products, announces Innovative Blending, a household invention that revolutionizes the vending ... Juice & Smoothie Bars market is worth $2 billion," says Scott Cooper, CEO ...
Breaking Medicine News(10 mins):